ERBB2 and non-small cell lung carcinoma: In addition to T-DXd, zongertinib, a novel HER2-TKI, has been approved for previously treated patients with advanced ERBB2-mutated NSCLC by the FDA recently as it showed high efficacy and acceptable safety profiles.